{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:06:34Z","timestamp":1778857594610,"version":"3.51.4"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"vor","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005629","name":"Takeda Pharmaceuticals America Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005629","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL126974"],"award-info":[{"award-number":["HL126974"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.rpth.2024.102337","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T12:00:57Z","timestamp":1707134457000},"page":"102337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clot formation and fibrinolysis assays reveal functional differences among hemostatic agents in hemophilia A plasma"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1399-2689","authenticated-orcid":false,"given":"Lori A.","family":"Holle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3404-0939","authenticated-orcid":false,"given":"Jacob C.","family":"Pantazis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6161-1556","authenticated-orcid":false,"given":"Peter L.","family":"Turecek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2845-2303","authenticated-orcid":false,"given":"Alisa S.","family":"Wolberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2024.102337_bib1","first-page":"479","article-title":"Factor VIII replacement is still the standard of care in haemophilia A","volume":"17","author":"Aledort","year":"2019","journal-title":"Blood Transfus"},{"key":"10.1016\/j.rpth.2024.102337_bib2","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1538-7836.2006.01953.x","article-title":"Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study","volume":"4","author":"Feldman","year":"2006","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102337_bib3","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2015-10-675140","article-title":"Men with severe hemophilia in the United States: birth cohort analysis of a large national database","volume":"127","author":"Mazepa","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102337_bib4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/hae.13878","article-title":"SHP656, a polysialylated recombinant factor VIII (PSA-rFVIII): First-in-human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A","volume":"26","author":"Tiede","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102337_bib5","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/hae.12784","article-title":"Porcine recombinant factor VIII (Obizur; OBI-1; BAX801): product characteristics and preclinical profile","volume":"22","author":"Lillicrap","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102337_bib6","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/j.1365-2516.2012.02789.x","article-title":"Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A","volume":"18","author":"Kempton","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102337_bib7","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1046\/j.1538-7836.2003.00450.x","article-title":"Monitoring the bioavailability of FEIBA with a thrombin generation assay","volume":"1","author":"Varadi","year":"2003","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102337_bib8","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/clpt.1994.80","article-title":"Pharmacokinetics and pharmacodynamics of recombinant factor VIIa","volume":"55","author":"Lindley","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.rpth.2024.102337_bib9","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0140-6736(20)32722-7","article-title":"The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing","volume":"397","author":"Mancuso","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2024.102337_bib10","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/ijlh.13763","article-title":"Guidance for establishing a factor VIII testing protocol for the myriad of factor VIII products","volume":"44","author":"Marlar","year":"2022","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.rpth.2024.102337_bib11","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1053\/j.seminhematol.2015.10.003","article-title":"Laboratory monitoring of new hemostatic agents for hemophilia","volume":"53","author":"Pruthi","year":"2016","journal-title":"Semin Hematol"},{"key":"10.1016\/j.rpth.2024.102337_bib12","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.transci.2018.07.007","article-title":"Issues complicating precision dosing for factor VIII prophylaxis","volume":"57","author":"Valentino","year":"2018","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.rpth.2024.102337_bib13","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1055\/s-0042-1758870","article-title":"Factor VIII and factor IX activity measurements for hemophilia diagnosis and related treatments","volume":"49","author":"Bowyer","year":"2023","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.rpth.2024.102337_bib14","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1055\/s-0039-1688687","article-title":"Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays","volume":"119","author":"Adamkewicz","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102337_bib15","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/hae.13990","article-title":"Effects of emicizumab on aPTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors","volume":"26","author":"Bowyer","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102337_bib16","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jtha.2022.12.023","article-title":"The effect of a next generation factor VIII mimetic bispecific antibody (Mim8) on assays of factor VIII activity and thrombin generation","volume":"21","author":"Bowyer","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102337_bib17","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1055\/s-0043-1768660","article-title":"The use of bypassing treatment strategies in hemophilia and their effect on laboratory testing","volume":"49","author":"Pruthi","year":"2023","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.rpth.2024.102337_bib18","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1182\/blood-2011-06-362814","article-title":"Procoagulant activity induced by vascular injury determines contribution of elevated factor VIII to thrombosis and thrombus stability in mice","volume":"118","author":"Machlus","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102337_bib19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1160\/TH12-05-0316","article-title":"In\u00a0vitro and in\u00a0vivo evaluation of the effect of elevated factor VIII on the thrombogenic process","volume":"109","author":"Golder","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102337_bib20","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2141.2012.09134.x","article-title":"Elevated factor VIII levels and risk of venous thrombosis","volume":"157","author":"Jenkins","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2024.102337_bib21","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/01.ATV.21.5.731","article-title":"Elevated factor VIII levels and the risk of thrombosis","volume":"21","author":"Kamphuisen","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.rpth.2024.102337_bib22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/s-0037-1613747","article-title":"High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism","volume":"83","author":"Kraaijenhagen","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102337_bib23","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJM200008173430702","article-title":"High plasma levels of factor VIII and the risk of recurrent venous thromboembolism","volume":"343","author":"Kyrle","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102337_bib24","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1046\/j.1538-7836.2003.00444.x","article-title":"Enhanced in\u00a0vitro procoagulant and antifibrinolytic potential of superactive variants of recombinant factor VIIa in severe hemophilia A","volume":"1","author":"Lisman","year":"2003","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102337_bib25","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2141.2005.05820.x","article-title":"High dose factor VIIa enhances clot stability in a model of hemophilia B","volume":"131","author":"Wolberg","year":"2005","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.rpth.2024.102337_bib26","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1365-2516.2006.01345.x","article-title":"Influence of factor VIII on overall coagulability and fibrinolytic potential of haemophilic plasma as measured by global assay: monitoring in haemophilia A","volume":"12","author":"Goldenberg","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102337_bib27","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1161\/01.ATV.0000257204.82396.2b","article-title":"A\u00a0variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in\u00a0vitro model of hemophilia","volume":"27","author":"Allen","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.rpth.2024.102337_bib28","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.thromres.2011.04.009","article-title":"Recombinant factor VIIa analog NN1731 (V158D\/E296V\/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasma","volume":"128","author":"Gray","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2024.102337_bib29","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/j.1538-7836.2012.04790.x","article-title":"Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma","volume":"10","author":"Gorczyca","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102337_bib30","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1182\/blood-2012-01-401620","article-title":"Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model","volume":"119","author":"Hilden","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102337_bib31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/rth2.12034","article-title":"Clot stability as a determinant of effective factor VIII replacement in hemophilia A","volume":"1","author":"Leong","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102337_bib32","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1055\/s-0040-1710032","article-title":"Synergistic effect of bypassing agents and sequence identical analogue of emicizumab and fibrin clot structure in the in\u00a0vitro model of hemophilia A","volume":"4","author":"Zong","year":"2020","journal-title":"TH Open"},{"key":"10.1016\/j.rpth.2024.102337_bib33","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1111\/hae.13961","article-title":"Emicizumab improves the stability and structure of fibrin clot derived from factor VIII-deficient plasma, similar to the addition of factor VIII","volume":"26","author":"Shimonishi","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102337_bib34","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/bjh.16574","article-title":"Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis-treated haemophilia A patients with inhibitors","volume":"190","author":"Furukawa","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2024.102337_bib35","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/j.1538-7836.2008.03032.x","article-title":"Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients","volume":"6","author":"Blanchette","year":"2008","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102337_bib36","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2015-03-630897","article-title":"Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A","volume":"126","author":"Konkle","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102337_bib37","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/2040620717720861","article-title":"Review of recombinant anti-haemophilic porcine sequence factor VIII in adults with acquired haemophilia A","volume":"8","author":"Fosbury","year":"2017","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.rpth.2024.102337_bib38","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0040-1717114","article-title":"Pharmacokinetics and pharmacodynamics of emicizumab in persons with hemophilia A with factor VIII inhibitors: HAVEN 1 Study","volume":"121","author":"Schmitt","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102337_bib39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000071637","article-title":"Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay","volume":"33","author":"Turecek","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1016\/j.rpth.2024.102337_bib40","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/jth.12600","article-title":"Abnormal plasma clot structure and stability distinguish bleeding risk in patients with severe factor XI deficiency","volume":"12","author":"Zucker","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102337_bib41","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1046\/j.1538-7836.2003.00298.x","article-title":"What is all that thrombin for?","volume":"1","author":"Mann","year":"2003","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102337_bib42","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/jth.14203","article-title":"In\u00a0vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents","volume":"16","author":"Hartmann","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102337_bib43","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/ijlh.14021","article-title":"The combination of emicizumab and recombinant factor VIII in plasma: which assays can we use for accurate measurement?","volume":"45","author":"Bowyer","year":"2023","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.rpth.2024.102337_bib44","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/hae.14359","article-title":"Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in\u00a0vivo global haemostasis assays","volume":"27","author":"Kizilocak","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102337_bib45","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/hae.14213","article-title":"Comparison of bypassing agents in patients on emicizumab using global hemostasis assays","volume":"27","author":"Kizilocak","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102337_bib46","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102337_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12546","article-title":"Tranexamic acid evidence and controversies: an illustrated review","volume":"5","author":"Relke","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102337_bib48","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.transci.2018.07.008","article-title":"Novel assays in the coagulation laboratory: a clinical and laboratory perspective","volume":"57","author":"Teichman","year":"2018","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.rpth.2024.102337_bib49","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1160\/TH09-03-0180","article-title":"Effects of tissue factor, thrombomodulin, and elevated clotting factor levels on thrombin generation in the calibrated automated thrombogram","volume":"102","author":"Machlus","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102337_bib50","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1365-2516.2010.02336.x","article-title":"Variability of thromboelastographic responses following the administration of rFVIIa to haemophilia A dogs supports the individualization of therapy with a global test of haemostasis","volume":"16","author":"Othman","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102337_bib51","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1182\/blood-2010-06-291906","article-title":"Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery","volume":"116","author":"Dargaud","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102337_bib52","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1111\/hae.13157","article-title":"Recombinant porcine factor VIII for high-risk surgery in paediatric congenital haemophilia A with high-titre inhibitor","volume":"23","author":"Croteau","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2024.102337_bib53","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1111\/jth.13743","article-title":"Subcommittee on Factor VIII, Factor IX, and Rare Coagulation Disorders. Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH","volume":"15","author":"Dargaud","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2024.102337_bib54","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1046\/j.1365-2141.1997.4463256.x","article-title":"Platelet activity of high-dose factor VIIa is independent of tissue factor","volume":"99","author":"Monroe","year":"1997","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.rpth.2024.102337_bib55","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1053\/j.seminhematol.2008.03.008","article-title":"Use of the thrombin generation test to evaluate response to treatment with recombinant activated factor VII","volume":"45","author":"Dargaud","year":"2008","journal-title":"Semin Hematol"},{"key":"10.1016\/j.rpth.2024.102337_bib56","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/hae.14684","article-title":"Safety of FEIBA and emicizumab (SAFE): dose escalation study evaluating the safety of in\u00a0vivo administration of activated prothrombin complex concentrate in haemophilia A patients on emicizumab","volume":"29","author":"Kizilocak","year":"2023","journal-title":"Haemophilia"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924000244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037924000244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:28:48Z","timestamp":1762864128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037924000244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2475037924000244"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102337","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clot formation and fibrinolysis assays reveal functional differences among hemostatic agents in hemophilia A plasma","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102337","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102337"}}